RxDoctor Payments Data

Michael Hall, MD

Addiction Medicine · du Bois, PANPI 1780688366

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (38.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Siemens Medical Solutions USA, Inc. accounts for 60.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $1,871 and has fallen 89.0% since, to $207 in 2025. Among addiction medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,615in general payments, 2019–2025

Across 40 payments — averaging $90.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$2K
  • Verathon Inc.$400
  • Indivior Inc.$358
  • Regeneron$324
  • Alkermes, Inc.$231
  • Braeburn Inc.$56
  • plus $46 from 1 others

What the payments were for

  • Consulting fees$1,22534%
  • Speaking & faculty fees$1,37538%
  • Travel & lodging$3249%
  • Food & beverage$69219%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,615 in reported general payments places this provider in the 90th percentile of 82 addiction medicine providers in Pennsylvania.

See all addiction medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,280
Medicare patients
12
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine43$87,181
VivitrolNaltrexone Microspheres37$59,412
BrixadiBuprenorphine22$34,485
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl167$10,782
Buprenorphine Hcl43$855
Naltrexone Hcl23$783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade$358$87,18143 claims
Alkermes, Inc.Vivitrol$231$59,41237 claims
Braeburn Inc.Brixadi$56$34,48522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 82 addiction medicine providers in Pennsylvania.

Other addiction medicine in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →